Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.34 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.34 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.34 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550720 | 0.92 | TRPV1 (0.37) | DRD2HSPA5HSPA8HSPA9HSPA2 | |
| SCHEMBL1550596 | 0.92 | NTRK1 (0.39) | NTRK1DRD2HSPA5HSPA8HSPA9 | |
| SCHEMBL1549551 | 0.92 | GHSR (0.41) | DRD2HSPA5HSPA8HSPA9HSPA2 | |
| SCHEMBL16457024 | 0.92 | GHSR (0.41) | DRD2HSPA5HSPA8HSPA9HSPA2 | |
| SCHEMBL19856902 | 0.91 | HTR2C (0.37) | DRD2HSPA5HSPA8HSPA9HSPA2 | |
| SCHEMBL1549343 | 0.91 | HTR2C (0.37) | DRD2HSPA5HSPA8HSPA9HSPA2 | |
| SCHEMBL1550494 | 0.90 | DRD2 (0.38) | DRD2HSPA5HSPA8HSPA9HSPA2 | |
| SCHEMBL16456898 | 0.90 | DRD2 (0.38) | DRD2HSPA5HSPA8HSPA9HSPA2 | |
| SCHEMBL1550985 | 0.89 | NTRK1 (0.37) | NTRK1DRD2HSPA5HSPA8HSPA9 | |
| SCHEMBL1550758 | 0.89 | NAMPT (0.40) | DRD2HSPA5HSPA8HSPA9HSPA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925857-B1 | USE OF TRPV4 ANTAGONISTS TO AMELIORATE HYDROCEPHALUS AND RELATED MATERIALS AND METHODS | UNIV INDIANA RES & TECH CORP (US) | 2018-02-14 | — | — | EP | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | claimed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | claimed |
| JP-2011529082-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | claimed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | NTRK1 1257/4885DRD2 928/4885HSPA5 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.